A new combination immunotherapy approach with anti-PD-L1 and HER2/neu loaded dendritic cell vaccine along with saponin adjuvant

被引：0
|
作者：
Ozverel, C. S. [1 ]
Karaboz, I. [1 ]
Nalbantsoy, A. [2 ]
机构：
[1] Ege Univ, Dept Biol, Fac Sci, Izmir, Turkey
[2] Ege Univ, Bioengn Dept, Fac Engn, Izmir, Turkey
来源：
EUROPEAN JOURNAL OF CANCER | 2018年 / 92卷
关键词：
D O I：
10.1016/j.ejca.2018.01.018
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P01.05
引用
收藏
页码：S6 / S7
页数：5
相关论文
共 31 条
  • [21] A Novel Dendritic Cell-based Immunization Approach for the Induction of Durable Th1-polarized Anti-HER-2/neu Responses in Women With Early Breast Cancer
    Koski, Gary K.
    Koldovsky, Ursula
    Xu, Shuwen
    Mick, Rosemarie
    Sharma, Anupama
    Fitzpatrick, Elizabeth
    Weinstein, Susan
    Nisenbaum, Harvey
    Levine, Bruce L.
    Fox, Kevin
    Zhang, Paul
    Czerniecki, Brian J.
    JOURNAL OF IMMUNOTHERAPY, 2012, 35 (01) : 54 - 65
  • [22] A New Plasmacytoid Dendritic Cell-Based Vaccine in Combination with Anti-PD-1 Expands the Tumor-Specific CD8+T Cells of Lung Cancer Patients
    Hannani, Dalil
    Leplus, Estelle
    Laurin, David
    Caulier, Benjamin
    Aspord, Caroline
    Madelon, Natacha
    Bourova-Flin, Ekaterina
    Brambilla, Christian
    Brambilla, Elisabeth
    Toffart, Anne-Claire
    Laulagnier, Karine
    Chaperot, Laurence
    Plumas, Joel
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (03)
  • [23] Preliminary efficacy and safety results of KN026 (a HER2-targeted bispecific antibody) in combination with KN046 (an anti-PD-L1/CTLA-4 bispecific antibody) in patients (pts) with HER2-positive gastrointestinal tumors
    Gong, J.
    Shen, L.
    Luo, S.
    Dong, Z.
    Liu, D.
    An, S.
    Xu, J.
    Yang, J.
    Qi, Y.
    Men, J.
    Kong, L.
    Yang, Y.
    Xu, T.
    ANNALS OF ONCOLOGY, 2021, 32 : S1042 - S1042
  • [24] Vaccination with dendritic cells pulsed with apoptotic tumors in combination with Anti-OX40 and Anti-4-1BB monoclonal antibodies induces T cell-mediated protective immunity in Her-2/neu transgenic mice
    Cuadros, C
    Dominguez, AL
    Lollini, PL
    Croft, M
    Mittler, RS
    Borgström, P
    Lustgarten, J
    INTERNATIONAL JOURNAL OF CANCER, 2005, 116 (06) : 934 - 943
  • [25] SAKK 16/14: Anti-PD-L1 antibody durvalumab in addition to neo-adjuvant chemotherapy in patients with stage IIIA(N2) non-small cell lung cancer (NSCLC)
    Rothschild, S. I.
    Zippelius, A.
    Eboulet, E. I.
    Savic, S.
    Betticher, D.
    Bettini, A.
    Fruh, M.
    Jorger, M.
    Britschgi, C.
    Peters, S.
    Mark, M.
    Ochsenbein, A. F.
    Janthur, W. -D.
    Waibel, C.
    Mach, N.
    Gonzalez, M.
    Frosch, P.
    Goddar, G.
    Rusterholz, C.
    Pless, M.
    SWISS MEDICAL WEEKLY, 2020, : 3S - 3S
  • [26] Sequential Anti-PD1 Therapy Following Dendritic Cell Vaccination Improves Survival in a HER2 Mammary Carcinoma Model and Identifies a Critical Role for CD4 T Cells in Mediating the Response
    Kodumudi, Krithika N.
    Ramamoorthi, Ganesan
    Snyder, Colin
    Basu, Amrita
    Jia, Yongsheng
    Awshah, Sabrina
    Beyer, Amber P.
    Wiener, Doris
    Lam, Lian
    Zhang, Hongtao
    Greene, Mark, I
    Costa, Ricardo L. B.
    Czerniecki, Brian J.
    FRONTIERS IN IMMUNOLOGY, 2019, 10
  • [27] Preliminary safety and efficacy results of KN046 (an anti-PD-L1/CTLA-4 bispecific antibody) in combination with KN026 (a HER2-targeted bispecific antibody) in patients with metastatic HER2-positive breast cancer: A phase II trial
    Liu, Jieqiong
    Song, Chuangui
    Wang, Xiangcai
    Ni, Mingli
    Wang, Xujuan
    Chen, Lei
    Yang, Hongwei
    Zhao, Rusen
    Xu, Ting
    Shen, Lin
    CANCER RESEARCH, 2022, 82 (04)
  • [28] Immunogenicity and antitumor efficacy of a novel human PD-1 B-cell vaccine (PD1-Vaxx) and combination immunotherapy with dual trastuzumab/pertuzumab-like HER-2 B-cell epitope vaccines (B-Vaxx) in a syngeneic mouse model
    Kaumaya, Pravin T. P.
    Guo, Linlin
    Overholser, Jay
    Penichet, Manuel L.
    Bekaii-Saab, Tanios
    ONCOIMMUNOLOGY, 2020, 9 (01):
  • [29] A newly discovered PD-L1 B-cell epitope peptide vaccine (PDL1-Vaxx) exhibits potent immune responses and effective anti-tumor immunity in multiple syngeneic mice models and (synergizes) in combination with a dual HER-2 B-cell vaccine (B-Vaxx)
    Guo, Linlin
    Overholser, Jay
    Darby, Heather
    Ede, Nicholas J.
    Kaumaya, Pravin T. P.
    ONCOIMMUNOLOGY, 2022, 11 (01):
  • [30] An Idiotype Vaccine Strategy Utilizing Targeted NGS and Cell Free Protein Synthesis System Ensures Identification and Production of Human Idiotype Antigens, and Shows Promising Results in Preclinical Models of B-Cell Lymphoma with a Novel TLR7/8 AgonistBased Adjuvant and Anti-PD-L1 Antibody
    Moon, Sungho
    Chun, Miyeon
    Kim, Sangwoo
    Seo, Hanna
    Kim, Kyeong Eun
    Cho, Geummi
    Kim, Chul
    Yoon, Dok Hyun
    Lee, Yoon Se
    Kim, Tae Min
    Chung, Eun-Jae
    Chung, Junho
    BLOOD, 2023, 142
1234